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Abstract
Background: Experimental data suggest a role for iron in the course of tuberculosis (TB) infection, but there is limited
evidence on the potential effects of iron deficiency or iron overload on the progression of TB disease in humans. The aim of
the present analysis was to examine the association of iron status with the risk of TB progression and death.
Methodology/Principal Findings: We analyzed plasma samples and data collected as part a randomized micronutrient
supplementation trial (not including iron) among HIV-infected and HIV-uninfected TB patients in Dar es Salaam, Tanzania.
We prospectively related baseline plasma ferritin concentrations from 705 subjects (362 HIV-infected and 343 HIV-
uninfected) to the risk of treatment failure at one month after initiation, TB recurrence and death using binomial and Cox
regression analyses. Overall, low (plasma ferritin,30 mg/L) and high (plasma ferritin.150 mg/L for women and.200 mg/L
for men) iron status were seen in 9% and 48% of patients, respectively. Compared with normal levels, low plasma ferritin
predicted an independent increased risk of treatment failure overall (adjusted RR=1.95, 95% CI: 1.07 to 3.52) and of TB
recurrence among HIV-infected patients (adjusted RR=4.21, 95% CI: 1.22 to 14.55). High plasma ferritin, independent of C-
reactive protein concentrations, was associated with an increased risk of overall mortality (adjusted RR=3.02, 95% CI: 1.95 to
4.67).
Conclusions/Significance: Both iron deficiency and overload exist in TB patients and may contribute to disease progression
and poor clinical outcomes. Strategies to maintain normal iron status in TB patients could be helpful to reduce TB morbidity
and mortality.
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Introduction
With the expansion of high-quality directly observed treatment
short course programs over the last 15 years, important progress
has been made in reducing the global burden of tuberculosis (TB).
TB disease, however, still carries an appreciable mortality,
representing the world’s second leading cause of death from a
single infectious agent [1]. Variability in disease progression, with
approximately 10% of TB-infected individuals developing clinical
disease in the absence of immunosuppression [2], suggests that
individual factors may play a role in the response to infection.
Micronutrient status, an important contributor to immune
function and cytokine kinetics, has been increasingly suggested to
play a role in the individual response to TB. The potential role of
iron in TB was first reported in 1872 when a French physician
noted a greater risk of relapse among recovering TB patients given
iron-rich supplements [3]. Considerable experimental evidence
has since accumulated demonstrating the contribution of iron
availability to mycobacterial growth in serum, cells and mice
[4,5,6,7].
Nevertheless, there are few reports on host iron status at the
time of TB diagnosis, and limited epidemiological research has
been conducted on the potential effects of iron status on the
progression of TB disease. A small number of studies have shown
elevated iron levels to be associated with an increased risk of TB
infection and death from TB [8,9,10]. Iron deficiency has been
associated with impaired immune function in in vitro and in vivo
models [11,12], but evidence on the role of iron deficiency in the
context of human TB disease is limited.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37350To better understand the role of iron status in the progression of
TB, we used data collected from a micronutrient supplementation
trial conducted among adult TB patients in Dar es Salaam,
Tanzania to assess the association of iron status with clinical
outcomes in TB. We used plasma levels of ferritin, an iron storage
protein that circulates in quantities proportional to the amount of
iron storage, as an indicator of iron status and related high and low




Between April 2000 and April 2005, 887 adults with pulmonary
TB (471 HIV-infected and 416 HIV-uninfected) were enrolled in a
randomized, placebo-controlled trial to examine the effect of
micronutrient supplementation on sputum conversion (defined as
the finding of an acid-fast bacilli [AFB] negative sputum culture) at
one month, TB recurrence, and mortality. Details of the trial have
been published elsewhere (ClinicalTrials.gov identifier
NCT00197704) [13]. Patients were randomized, stratified by
HIV status, to receive a daily oral dose of multiple micronutrients
(not including iron) or placebo; all patients received an eight-
Table 1. Socio-demographic and clinical characteristics of 705 tuberculosis patients at baseline by level of iron status.
Baseline iron status
a
Low Normal High P
b
n( % ) n( % ) n( % )
All 65 (9) 302 (43) 338 (48)
Socio-demographic characteristics
Female 40 (62) 108 (36) 80 (24) ,0.0001
Median age, y (IQR) 27 (23, 31) 30 (24, 36) 32 (27, 39) ,0.0001
Highest educational attainment 0.46
None 7 (11) 37 (12) 26 (8)
Incomplete primary 7 (11) 34 (11) 34 (10)
Incomplete secondary 46 (71) 202 (67) 236 (70)
Secondary or higher 5 (8) 29 (10) 42 (12)
Median household size
c (IQR) 4 (3, 7) 4 (2, 6) 4 (2, 6) 0.54
Median number of household assets (IQR) 1 (0, 2) 1 (0, 2) 2 (0, 3) 0.0007
Median amount spent on food (IQR)
d 375 (250, 667) 500 (286, 750) 500 (286, 750) 0.43
Clinical characteristics
Hemoglobin ,11 g/dL 46 (71) 174 (58) 214 (63) 0.09
C-reactive protein .10 mg/L 30 (46) 208 (69) 291 (86) ,0.0001
HIV-infected 29 (45) 138 (46) 195 (58) 0.005
History of tuberculosis disease 45 (69) 206 (68) 214 (64) 0.39
Number of colonies in AFB culture 0.32
None 4 (6) 18 (6) 18 (5)
1–100 38 (58) 167 (55) 165 (49)
.100 23 (35) 116 (39) 155 (46)
Karnofsky score ,70% 2 (3) 30 (10) 46 (14) 0.03
Median BMI (kg/m
2, IQR) 19 (18, 22) 19 (18, 21) 19 (17, 21) 0.05
Median CD4 T cell count (cells/uL, IQR) 546 (374, 832) 530 (316, 752) 473 (214, 679) 0.005
WHO HIV clinical stage
e 0.79
Stage 3 18 (90) 93 (92) 137 (90)
Stage 4 2 (10) 8 (8) 16 (10)
HIV RNA.50,000 copies/mL
e 11 (42) 62 (56) 91 (55) 0.41
Values are n (%), unless otherwise stated. Totals may be less than 705 due to missing values.
Abbreviations used: IQR, inter-quartile range, AFB, acid-fast bacilli, BMI, body mass index, WHO, World Health Organization.
aBaseline iron status was categorized as low: plasma ferritin ,30 mg/L; normal: plasma ferritin 30 to #150 mg/L for women and 30 to #200 mg/L for men; and high:
plasma ferritin .150 mg/L for women and .200 mg/L for men.
bP value is from the x
2 test for proportions and the Kruskal-Wallis test for continuous measures.
cHousehold size was defined as the number of people eating in the household.
dAmount spent on food is in Tanzanian shillings per person per day. At the time of the start of the study in 2000, the mean exchange rate was 1 USD=799 Tanzanian
shillings.
eWHO clinical stage and HIV RNA assessed only in HIV-infected patients, n=362.
doi:10.1371/journal.pone.0037350.t001
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Tanzania National Tuberculosis and Leprosy Program guidelines.
Ethics statement
The study was approved by the institutional review boards of
Muhimbili University of Health and Allied Sciences, the
Tanzanian National AIDS Control Program of the Tanzanian
Ministry of Health, and Harvard School of Public Health. Written
informed consent was obtained from all patients.
Follow-up
Monthly follow-up was conducted by research nurses at the
study clinics and included anthropometric assessment and
recording of any illness in the previous month. Patients were
followed until death, loss-to-follow-up or study closure in August
Table 2. Association of baseline iron status with treatment failure at one month after initiation.
Iron status
a # Events/ Unadjusted Model Multivariate Model
b
No. at risk Relative risk (95% CI) Relative risk (95% CI)
Overall
Low 12/50 1.70 (0.94, 3.07) 1.95 (1.07, 3.52)
Normal 30/212 1.00 1.00
High 52/251 1.46 (0.97, 2.21) 1.54 (1.00, 2.39)
HIV-infected patients
Low 5/22 1.82 (0.71, 4.63) 2.21 (0.96, 5.10)
Normal 12/96 1.00 1.00
High 21/141 1.19 (0.62, 2.31) 1.26 (0.63, 2.53)
HIV-uninfected patients
Low 7/28 1.61 (0.75, 3.48) 1.82 (0.82, 4.05)
Normal 18/116 1.00 1.00
High 31/110 1.82 (1.08, 3.05) 1.75 (1.04, 2.95)
aBaseline iron status was categorized as low: plasma ferritin ,30 mg/L; normal: plasma ferritin 30 to #150 mg/L for women and 30 to #200 mg/L for men; and high:
plasma ferritin .150 mg/L for women and .200 mg/L for men.
bAdjusted risk ratio from a log-binomial regression model adjusting for baseline covariates including sex, age (years), money spent on food per person per day (,500,
$500 TSH), number of colonies in AFB culture, Karnofsky score (,70%, $70%), BMI (kg/m
2), history of TB disease (yes/no), HIV infection status, CD4 T cell count (cells/
uL) and log HIV RNA (copies/mL), trial regimen and C-reactive protein (mg/L).
P value, test for interaction by HIV infection status=0.55.
doi:10.1371/journal.pone.0037350.t002
Table 3. Association of baseline iron status with tuberculosis recurrence.
Iron status
a # Events/ Unadjusted Model Multivariate Model
b
Person-mo Relative risk (95% CI) Relative risk (95% CI)
Overall
Low 6/634 0.91 (0.38, 2.18) 1.05 (0.42, 2.63)
Normal 34/3,819 1.00 1.00
High 34/3,398 1.04 (0.65, 1.67) 1.39 (0.80, 2.39)
HIV-infected patients
Low 5/275 2.52 (0.85, 7.54) 4.21 (1.22, 14.55)
Normal 9/1,557 1.00 1.00
High 17/1,770 1.53 (0.68, 3.44) 2.43 (0.93, 6.34)
HIV-uninfected patients
Low 1/358 0.23 (0.03, 1.71) 0.23 (0.03, 1.72)
Normal 25/2,262 1.00 1.00
High 17/1,628 0.91 (0.49, 1.68) 1.09 (0.56, 2.10)
aBaseline iron status was categorized as low: plasma ferritin ,30 mg/L; normal: plasma ferritin 30 to #150 mg/L for women and 30 to #200 mg/L for men; and high:
plasma ferritin .150 mg/L for women and .200 mg/L for men.
bAdjusted relative risk from a proportional hazards model adjusting for baseline covariates including sex, age (years), money spent on food per person per day (,500,
$500 TSH), number of colonies in AFB culture, Karnofsky score (,70%, $70%), BMI (kg/m
2), history of TB disease (yes/no), HIV infection status, CD4 T cell count (cells/
uL) and log HIV RNA (copies/mL), trial regimen and C-reactive protein (mg/L).
P value, test for interaction by HIV infection status=0.02.
doi:10.1371/journal.pone.0037350.t003
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specimens for the measurement of hemoglobin and T-lymphocyte
subsets were collected at baseline; 1, 2, 5, 8, and 12 months after
treatment initiation; and every 6 months thereafter. Blood
collected at baseline, 2, 8 and 14 months among HIV-infected
patients was also measured for HIV RNA levels. HIV disease stage
was assessed every 3 months at physician visits according to the
WHO staging system for HIV disease.
Laboratory procedures
Sputum specimens were prepared and stained using the Ziehl-
Neelsen technique and examined for AFB using direct microscopy
by trained laboratory technicians. AFB-positive specimens were
cultured for M. tuberculosis using Lowenstein Jensen medium and
examined weekly for a maximum of 8 weeks. Plasma HIV RNA
levels in HIV-infected patients was determined using the Amplicor
HIV-1 Monitor assay version 1.5 (Roche Diagnostic Systems,
Branchburg, NJ). After study closure, in 2010 we drew on plasma
specimens stored at 280uC since collection to measure plasma
ferritin and C-reactive protein (CRP) using a particle-enhanced
immunoturbidimetric assay (Roche Diagnostics GmbH, Mann-
heim, Germany) in the Roche Cobas Integra 400 Plus analyzer.
Classification of iron status
We used plasma ferritin concentration as an indicator of iron
status. Ferritin is considered a reliable measure of iron status in
many settings, but as a positive acute phase reactant, concentra-
tions can increase during inflammation or infection even if iron
status is low. In the absence of an acute phase response, ferritin
concentrations ,12 to 15 mg/L are indicative of depleted iron
stores [14]; however, in the context of TB infection, a higher
threshold of ,30 mg/L has been suggested to increase sensitivity
of this indicator [15]. Ferritin concentrations consistent with high
iron status have varied in the literature, but it has been suggested
that levels of .150 mg/L for women and .200 mg/L for men are
indicative of iron overload [16]. In this analysis, we defined three
levels of iron status by baseline plasma ferritin concentration as
follows: low (plasma ferritin ,30 mg/L); normal (plasma ferritin 30
to #150 mg/L for women and 30 to #200 mg/L for men); and
high (plasma ferritin .150 mg/L for women and .200 mg/L for
men).
Statistical analysis
We compared subject characteristics at baseline by levels of
plasma ferritin using the x
2 test for categorical variables and the
Kruskal-Wallis test for continuous variables. We considered two
TB-related endpoints: treatment failure at one month, defined as
an AFB-positive sputum culture at one month from treatment
Table 4. Association of baseline iron status with mortality and HIV disease progression from WHO stage 3 to stage 4.
Iron status
a # Events/ Unadjusted Model Multivariate Model
b
Person-mo Relative risk (95% CI) Relative risk (95% CI)
Mortality
Overall
Low 7/2,801 0.97 (0.43, 2.18) 0.86 (0.36, 2.05)
Normal 34/13,345 1.00 1.00
High 83/12,375 2.54 (1.70, 3.79) 3.02 (1.95, 4.67)
HIV-infected patients
Low 6/990 0.85 (0.36, 2.04) 0.82 (0.33, 2.05)
Normal 33/4,625 1.00 1.00
High 72/5,409 1.86 (1.23, 2.81) 2.70 (1.72, 4.24)
HIV-uninfected patients
Low 1/1,812 4.71 (0.30, 75.24) 2.50 (0.13, 47.32)
Normal 1/8,720 1.00 1.00
High 11/6,967 13.52 (1.75, 104.49) 12.81 (1.63, 101.02)
HIV disease progression
Low 9/522 1.28 (0.61, 2.71) 1.70 (0.71, 4.08)
Normal 30/2,211 1.00 1.00
High 40/2,471 1.16 (0.72, 1.87) 1.25 (0.73, 2.14)
HIV disease progression or death
Low 9/612 0.97 (0.47, 1.99) 0.82 (0.37, 1.84)
Normal 41/2,563 1.00 1.00
High 71/3,199 1.36 (0.93, 2.00) 1.34 (0.87, 2.06)
aBaseline iron status was categorized as low: plasma ferritin ,30 mg/L; normal: plasma ferritin 30 to #150 mg/L for women and 30 to #200 mg/L for men; and high:
plasma ferritin .150 mg/L for women and .200 mg/L for men.
bAdjusted relative risk from a proportional hazards model adjusting for baseline covariates including sex, age (years), money spent on food per person per day (,500,
$500 TSH), number of colonies in AFB culture, Karnofsky score (,70%, $70%), BMI (kg/m
2), history of TB disease (yes/no), HIV infection status, CD4 T cell count (cells/
uL) and log HIV RNA (copies/mL), trial regimen and C-reactive protein (mg/L).
P value, test for interaction by HIV infection status for mortality endpoint=0.22.
doi:10.1371/journal.pone.0037350.t004
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one month among those who were culture negative by one month
after treatment initiation. Recurrence included both endogenous
re-activation and exogenous re-infection, as the two could not be
distinguished in the current study. Log-binomial regression was
used to assess the associations of baseline plasma ferritin with
treatment failure [17]. Cox proportional hazards regression was
used to assess the associations of baseline plasma ferritin with time
to TB recurrence and death. Among HIV-infected patients, we
also fit Cox proportional hazards regression models to examine the
relationship of plasma ferritin at baseline with time to HIV disease
progression from stage 3 to stage 4 and the combined endpoint of
death or HIV disease progression.
We adjusted for potential baseline confounders, including sex,
age (years), money spent on food (,500, $500 Tanzanian shillings
per person per day, equivalent to US $0.63 at the time of the start
of the study), number of colonies in AFB culture, Karnfosky score
(,70%, $70%), history of previous TB disease (yes/no), HIV
infection status (infected/uninfected), BMI (kg/m
2), CD4 T cell
count (cells/uL), log HIV RNA (copies/mL), as well as random-
ized trial regimen (micronutrient treatment/placebo). Given the
known influence of inflammation on plasma ferritin concentra-
tions, we additionally adjusted for CRP (mg/L), a reliable
indicator of inflammation, in all multivariate models. Continuous
covariates modeled using restricted cubic splines to allow for non-
linearity [18,19]. When non-linear associations were found, the
corresponding spline terms chosen through stepwise selection were
included in the model.
We assessed the associations of baseline plasma ferritin with
treatment failure, TB recurrence, and mortality in the overall
cohort and according to HIV infection status. Because plasma
ferritin concentrations increase during the acute phase response
and high levels may not represent high iron status in the presence
of inflammation, we also assessed the association of high plasma
ferritin among subjects with low levels of CRP (CRP#10 mg/L)
when a significant association was observed overall. Analyses were
performed using SAS version 9.1 (SAS Institute Inc, Cary, NC). P
values were two-sided and considered statistically significant at
P,0.05.
Results
Among the 887 TB patients included in the parent trial, 705
(79%) had a plasma ferritin measurement at baseline and were
eligible for analysis. Overall, 9% of patients had low plasma
ferritin and 48% had high levels. The baseline socio-demographic
and clinical characteristics of patients according to level of plasma
ferritin are shown in Table 1. Patients with high plasma ferritin
were more likely to be female and older but were similar to
patients with low and normal plasma ferritin with respect to other
socio-demographic characteristics, including education, household
size, and money spent on food. The prevalence of high CRP
concentrations increased and CD4 T cell counts decreased with
increasing plasma ferritin concentrations, but other clinical
characteristics (i.e. history of previous TB disease, mean hemo-
globin, and BMI) did not significantly differ by plasma ferritin
level.
Information of sputum culture status at one month after
treatment initiation was available for 513 (73%) patients with a
plasma ferritin measurement at baseline, of whom 94 (18%) were
culture positive at one month. Compared with patients with
normal plasma ferritin, the risk of treatment failure at one month
was independently increased among those with low levels of
plasma ferritin (Table 2, adjusted RR=1.95, 95% confidence
interval (CI): 1.07 to 3.52). We found no evidence for an
association of the risk of treatment failure with high levels of
plasma ferritin.
We next assessed the association between plasma ferritin and
TB recurrence. Of the 394 patients with a negative culture at one
month, 74 (19%) had a subsequent positive culture. The risk of TB
recurrence was modified by HIV infection status (P for interac-
tion=0.02). Neither low nor high plasma ferritin significantly
predicted TB recurrence among HIV-uninfected patients
(Table 3). In contrast, among HIV-infected patients and after
adjustment for potential confounders including CRP, low plasma
ferritin was associated with an independent 4.2-fold increase (95%
CI: 1.22 to 14.55) in the risk of TB recurrence.
With a median duration of 47 months of follow-up, we
documented 124 deaths, 111 among HIV-infected patients and
13 among HIV-uninfected patients. The relative risks of mortality
by level of plasma ferritin are shown in Table 4. After adjustment
for potential confounders including CRP, high plasma ferritin was
associated with an independent 3-fold increase in the risk of death
overall (95% CI: 1.95 to 4.67). Because plasma ferritin concen-
trations increase during the acute phase response and high levels
may not represent high iron status in the presence of inflamma-
tion, we also assessed the association of high plasma ferritin with
mortality among subjects without evidence of inflammation.
Among subjects with CRP#10 mg/L (n=176), high plasma
ferritin remained a strong, significant predictor of the risk of death
(adjusted RR=5.05, 95% CI: 2.42 to 10.54).
Discussion
Our results from a large prospective study of TB patients
provide additional evidence for the role of host iron status in TB
disease progression. We found that low plasma ferritin was
associated with an increased risk of treatment failure at one month
after treatment initiation overall and of TB recurrence among
HIV-infected patients. High plasma ferritin, independent of the
acute phase response, was associated with an increased risk of
mortality.
We found a somewhat small proportion (9%) of patients in this
population to be iron deficient, as defined by plasma ferritin. Our
results are consistent with the low prevalence of iron deficiency
reported in similar cohorts of TB patients [20], 8.5% of women
and 2.9% of men with serum ferritin ,24 mg/L in rural Tanzania
[21] and 0% of patients with serum ferritin ,14 mg/L in South
Africa [22]). Many patients in this study, however, showed
evidence of an acute phase response reflected by elevated CRP
concentrations. Since plasma ferritin concentrations increase
during the acute phase response, it is possible that the true
burden of iron deficiency is under-estimated when assessed using
ferritin concentrations. In a previous analysis from this cohort,
53% of patients at baseline were found to be iron deficient as
defined by mean corpuscular volume ,80 fl [23].
We found strong, positive associations of low iron status with the
risk of treatment failure at one month overall and of TB
recurrence among HIV-infected patients. These results are based
on a relatively small number of events and should be confirmed in
larger cohorts. They are, however, consistent with the hypothesis
that iron deficiency may impair immune function [11,12] and lead
to increased susceptibility or progression of TB disease. Experi-
mental evidence suggests that iron deficiency may compromise
cell-mediated immunity by decreasing lymphocyte activation and
proliferation and reducing macrophage bactericidal activity
[24,25]. Iron deficiency has also been shown experimentally to
alter the Th1/Th2 cytokine balance, promoting a strong Th2
Iron Status Predicts Clinical Outcomes in TB
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[26,27,28]. Evidence underlying the potential effect of iron
deficiency in TB is experimental and requires extrapolation from
in vitro and animal models to humans, but we suggest that the
potential magnitude of increased risk and plausible mechanisms
support the need for further study. Future studies on the potential
impact of host iron deficiency in TB progression should aim to use
multiple markers of iron deficiency, including those less influenced
by the acute phase response such as soluble transferrin receptor.
We found that elevated ferritin levels were strongly associated
with an increased risk in mortality. High splenic iron was
associated with an increased risk of death from TB in an autopsy
series from South Africa [10]. High dietary iron [9] and bone
marrow macrophage iron [8] have also been associated with
increased odds of TB. One hypothesized mechanism linking high
iron status to TB disease susceptibility and progression is that
increased iron availability stimulates microbial growth. Evidence
from in vitro and animal models suggests that iron loading can
increase mycobacterium replication [4,5,6]. Laboratory studies
also indicate that iron loading of macrophages, which are critical
to the body’s defense against TB, impairs the ability of these cells
to inhibit the growth of intracellular mycobacteria [29,30]. Recent
evidence from TB patients in rural Zimbabwe also suggests that
increased dietary iron may attenuate the Th1 immune response
[31], which is thought to contribute to the control of TB infection.
Because ferritin is a positive acute phase reactant, it can be
argued that elevated ferritin concentrations could reflect either
increased iron status or inflammation in the setting of normal iron
status. We examined the association of high plasma ferritin levels
independent of inflammation in two ways: multivariate adjustment
for CRP and restriction to low levels of CRP. We would expect
both methods to attenuate the observed associations for high
plasma ferritin if due to inflammation and not iron status per se.
After multivariate adjustment and restriction, however, we found
the observed associations were not attenuated but rather
strengthened. While residual confounding remains a possibility,
our finding that high plasma ferritin remained significantly
associated with poor clinical outcomes after accounting for CRP
concentrations provides support for the clinical importance of iron
overload in TB progression.
This study has several limitations. First, the interpretation of
plasma ferritin concentrations is complicated during conditions
eliciting an acute phase response. We used multivariate adjustment
and stratification by CRP concentration to help better relate high
plasma ferritin to iron status but are unable to distinguish other
pathways that may contribute to elevated iron status, such as high
dietary intake of iron and factors associated with its bioavailability,
or genetic polymorphisms. Second, we did not have data on
several predictors of iron status and known risk factors for TB
infection, including smoking, alcohol history and diabetes. The
prevalence of these factors is not likely high in this population
[32,33], but we cannot rule out the contribution of confounding to
the observed associations. Third, it has been shown that
antiretroviral treatment for HIV may modulate iron status [34],
but at the time of this study, antiretroviral treatment was not
available to the majority of HIV-infected individuals in Tanzania.
Analysis within this cohort allows us to better understand any
potential adverse effect of iron status on the natural history of TB-
HIV co-infection but may limit the generalizability of these
findings as antiretroviral therapy becomes more accessible.
Anemia is highly prevalent among TB patients [20,35] and is
often treated with iron supplementation, irrespective of etiology.
Concerns have been raised about the safety of iron supplemen-
tation and iron overload in the context of infectious diseases, but
the available evidence is conflicting [10,36,37,38]. While our
results are not conclusive, they are in agreement with the
hypotheses that iron imbalance at both ends of the continuum
exist in TB patients and may contribute to disease progression and
poor clinical outcomes.
These results have practical clinical and programmatic impli-
cations. In contrast to liver biopsy and bone marrow aspiration,
the gold standards for the diagnosis of iron overload and
deficiency, plasma ferritin is relatively easy and inexpensive to
measure. Thus where extensive clinical investigations are imprac-
tical, we show that routine screening for ferritin may be used to
identify those at risk for poor clinical outcomes. The close
monitoring of patients with abnormal ferritin values could be used
to reduce TB morbidity and mortality. Programs recommending
iron supplementation for the treatment of anemia in regions with a
high burden of TB may also consider targeting the use of
supplemental iron to those patients with evidence of iron
deficiency. Further study in TB-infected populations is needed to
better understand the potential benefit of treating anemia with
iron supplementation and risk of increasing iron status to
potentially hazardous levels.
In conclusion, we found both low and high iron status to be
associated with poor treatment outcomes and mortality in TB.
The plausible mechanisms, consistency with previous results, and
the magnitude of the observed associations strongly suggest that
the potential risks associated with iron imbalance should be
investigated further. Continued advances in our understanding of
how iron status may modulate the pathogenesis and progression of
TB could be of critical importance to improving the clinical
management of TB patients.
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